Condition: Niemann-Pick Type C Disease · Sponsor: Azafaros B.V.
An 18-month double-blind, randomized, placebo-controlled, multicenter, Phase 3 study to evaluate the safety and efficacy of oral nizubaglustat (AZ-3102) in late-infantile and juvenile forms of Niemann-Pick type C disease
This description comes directly from the study's public registry record.
Patient Advocacy Representative · Please reach out by email · info@azafaros.com
Contact for Healthcare Professionals · Please reach out by email · medinfo@azafaros.com
Always discuss trial participation with your own doctor first.
| UCSF Children's Hospital and Research Center at Oakland | Oakland, California, United States | Recruiting |
| University of Minnesota Medical School | Minneapolis, Minnesota, United States | Not Yet Recruiting |
| Mayo Clinic Children's Center - PIN | Rochester, Minnesota, United States | Recruiting |
| Children's Medical Center Dallas | Dallas, Texas, United States | Recruiting |
| Lysosomal Rare Disorders Research and Treatment Center | Fairfax, Virginia, United States | Recruiting |
| Hospital Universitario Austral | Ciudad Autónoma Buenos Aires, Buenos Aires, Argentina | Recruiting |
| Hospital de Niños de La Santisima Trinidad | Córdoba, Córdoba Province, Argentina | Recruiting |
| Women's and Children's Hospital | North Adelaide, South Australia, Australia | Recruiting |
| Royal Melbourne Hospital | Parkville, Victoria, Australia | Recruiting |
| Royal Children's Hospital Melbourne - PIN | Parkville, Victoria, Australia | Not Yet Recruiting |
| Instituto Fernandes Figueira | Rio de Janeiro, Rio de Janeiro, Brazil | Recruiting |
| Hospital de Clinicas de Porto Alegre (HCPA) - PPDS | Porto Alegre, Rio Grande do Sul, Brazil | Recruiting |
+ 23 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07082725